#United States #Chicago #FDA #Sarfaraz Niazi #conflict of interest

Regulatory Expert Calls for Action on Conflict-of-Interest Policies

In a significant move towards enhancing the transparency of FDA advisory committees, Dr. Sarfaraz K. Niazi, an adjunct professor at the University of Illinois Chicago and a regulatory science authority, has formally petitioned the U.S. Food and Drug Administration (FDA) requesting immediate action to establish long-overdue conflict-of-interest (COI) guidelines. This citizen petition addresses a rising concern over the integrity of the FDA's advisory committees, which play a critical role in high-stakes regulatory decisions involving public health and safety.

Dr. Niazi's petition comes in the wake of alarming findings by the U.S. Government Accountability Office (GAO), which revealed that the FDA has failed to finalize necessary COI guidance for advisory committees for over 13 years since a legislative mandate under the Food and Drug Administration Safety and Innovation Act (FDASIA) was enacted in 2012. Without a clear timeline for completion, the lack of definitive guidance raises serious questions about how financial conflicts are evaluated and managed within these advisory bodies.

Dr. Niazi, emphasizing the importance of transparent and consistently applied COI standards, pointed out that the current absence of finalized guidelines generates uncertainty. He stated, "The integrity of FDA advisory committees depends on transparent and consistently applied conflict-of-interest standards. The current absence of finalized guidance creates uncertainty around how financial conflicts are evaluated and managed, particularly in high-stakes regulatory decisions."

Highlighting the gravity of the situation, the petition outlines troubling statistics related to the lack of oversight in COI evaluation. From 2018 to 2024, advisory committees reported more than 120 instances of recusals, alongside over 50 waivers granted to members with known financial conflicts. These figures indicate the critical need for better COI regulations and underscore how essential this matter is for the integrity of regulatory processes.

Notably, the FDA previously rescinded its descriptions of COI evaluation practices in 2019 without issuing any updated information since then. The petition calls for the FDA to establish a clear timeline for the issuance of COI guidelines and to implement interim evaluation criteria that can address current concerns. It urges the agency to adopt a standardized and auditable framework while also considering independent oversight mechanisms to further enhance accountability.

Dr. Niazi has long been a champion of regulatory policy reform, and with this petition, he aims to reiterate the FDA's crucial role as a global leader in regulatory science. He believes that reinforcing transparency and governance mechanisms will not only strengthen the credibility of FDA advisory committees but also contribute to better regulatory outcomes.

The petition has been formally submitted through Regulations.gov, creating an administrative record that compels the FDA to respond. Moreover, copies have also been sent to Congressional oversight and appropriations committees to ensure that the issue is receiving the necessary attention.

In summary, this petition by Dr. Sarfaraz K. Niazi represents a pivotal moment in the drive towards regulatory integrity at the FDA. By calling for long-neglected COI guidelines, the petition seeks not only to rectify a historical oversight but also to safeguard the public's trust in regulatory decisions that ultimately shape healthcare and safety standards in the United States. As this issue unfolds, all eyes will be on the FDA to see how it addresses the urgent call for action to restore integrity to its advisory committees.